Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ809811-0,55
KB0,00
PKN64,0664,160,34
Msft-0,04
Nokia4,674,7495-0,30
IBM-0,26
Mercedes-Benz Group AG62,3662,38-0,21
PFE0,74
25.11.2022 23:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 25.11.2022 20:20:00
Vertex Pharma (VRTX.O, NASDAQ Cons)
Závěr k 23.11.2022 Změna (%) Změna (USD) Objem obchodů (ks)
316,16 -1,01 -3,18 713 610
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.11.2022
Popis společnosti
Obecné informace
Název společnostiVertex Pharmaceuticals Incorporated
TickerVRTX
Kmenové akcie:Ordinary Shares
RICVRTX.O
ISIN-
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.12.2021 3 900
Akcie v oběhu k 21.10.2022 256 691 452
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice50 Northern Avenue
MěstoBOSTON
PSČ02210
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 173 416 393

Business Summary: Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Vertex Pharmaceuticals Incorporated revenues increased 20% to $6.63B. Net income increased 59% to $2.5B. Revenues reflect TRIKAFTA segment increase of 41% to $5.67B, Europe segment increase of 46% to $2.02B, United States segment increase of 9% to $4.24B. Net income benefited from Research and development Expenses - Bala decrease of 47% to $1.14B (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 26.11.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardJeffrey Leiden6601.04.202014.12.2011
President, Chief Executive Officer, DirectorReshma Kewalramani-01.04.202001.04.2018
Chief Financial Officer, Executive Vice PresidentCharles Wagner5310.04.201910.04.2019
Chief Operating Officer, Executive Vice PresidentStuart Arbuckle5604.08.202104.09.2012
Executive Vice President - Global Research, Chief Scientific OfficerDavid Altshuler57
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical OfficerCarmen Bozic5901.04.202001.04.2020
Executive Vice President, Chief Patient OfficerAmit Sachdev54
Executive Vice President, Chief of Cell and Genetic TherapiesBastiano Sanna47
Executive Vice President, Chief Regulatory and Quality OfficerOurania Tatsis5201.10.2019
Senior Vice President, Chief Accounting OfficerKristen Ambrose45